Chewable tablet containing montelukast sodium

A technology of montelukast sodium and chewable tablets, which is applied in the field of chewable tablets containing montelukast sodium, can solve the problem of not mentioning other effects of colorants, montelukast sodium is easy to change color when exposed to light, and inconvenient for mass production in workshops and other problems, to avoid the decomposition of visible light, improve the operability, and facilitate the production operation.
CN101773481BActive Publication Date: 2013-01-16LUNAN PHARMA GROUP CORPORATION
3 Cites 7 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
LUNAN PHARMA GROUP CORPORATION
Publication Date
2013-01-16

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention belongs to the field of medicine preparations, which particularly relates to a chewable tablet of montelukast sodium. Because the production process of the chewable tablet of the montelukast sodium needs the light shielding operation at present, the mass production is inconvenient, and the chewable tablet of the montelukast sodium has the defect of poorer stability. In the invention, zinc stearate and an opacifier of iron oxide red, iron oxide yellow and titanium dioxide are added into the auxiliary materials of a chewable tablet of montelukast, so that the content of relevant substances can be lowered, and the stability of the chewable tablet is enhanced.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of pharmaceutical preparations, in particular to a chewable tablet containing montelukast sodium. Background technique

[0002] Asthma is a chronic inflammatory disease characterized by tracheal hyperresponsiveness and reversible airway obstruction. As a common chronic disease, it afflicts nearly 10% of the population in developed countries, causing social and economic losses of tens of billions of dollars. In recent decades, the incidence of asthma at home and abroad, especially the incidence of childhood asthma is on the rise. According to the "epidemiological survey" in Shanghai in 2000, the incidence rate of asthma in children was 4.52%, which was 153.51% higher than that of 10 years ago, and children aged 2 to 5 accounted for 50.91%.

[0003] Montelukast is a highly selective cysteinyl leukotriene receptor antagonist developed by Merck, which can competitively antagonize the binding of leukotriene D4 to Cys-LT1...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More